LTR Pharma is an advanced clinical-stage biopharmaceutical company commercialising a rapid treatment for Erectile Dysfunction (ED) – SPONTAN®. 🔗 https://xitter.cf/t.co/V3eWjuahcz
Joined October 2023
- Tweets144
- Following23
- Followers115
- Likes0
Ethics approval received to study SPONTAN® in pulmonary arterial hypertension, a rare, currently incurable disease with a global therapeutics market estimated at US$8.0B (2024). Study expected to start this quarter. Read more: bit.ly/LTPPAH
$LTP #PAH #HeartDisease
More than 2,000 bottles of SPONTAN® dispensed in Australia under the TGA Special Access Scheme: bit.ly/4jyCjhQ
$LTP #LTRPharma #MensHealth
🎤 Investor webinar now live. Hear clinical insights from Sexologist and Nurse Practitioner Melissa Hadley Barrett and LTP Chief Medical Officer Prof Geoff Strange, plus a commercial update from LTP Executive Chair Lee Rodne 👉 bit.ly/4eexvKM
$LTP #LTRPharma #MensHealth
🇺🇸 $LTP confirms the first ROXUS® prescriptions have been fulfilled in the U.S. through Mavrox, Shed's men's health telehealth platform, less than three months after the Shed agreement was announced.
Read more here: bit.ly/4hDbUN6
$LTP #LTRPharma #MensHealth
📅 REGISTER NOW | Tues 6 Oct 10am AEDT, LTP Investor Webinar. Clinical insights from Melissa Hadley Barrett and CMO Prof Geoff Strange, plus a commercial update from Lee Rodne.
Register: bit.ly/4iVJTCR
$LTP #LTRPharma #MensHealth
Watch: Melissa Hadley Barrett on $LTP's SPONTAN® real-world data from #APCC2026. 93% response among treatment-experienced men seeking convenience and spontaneity.
🎥 bit.ly/LTPAPCCMHBVideo
$LTP #APCC2026 #LTRPharma #MensHealth
Final Phase II report in: SPONTAN® absorbs six times faster than oral vardenafil tablets, with no drug accumulation over five days, comparable PK in men 65+, and no serious adverse events. The FDA PK dataset is complete. bit.ly/4iSlRsm
#LTRPharma #Biotech #MensHealth
LTR Pharma has entered an exclusive pilot agreement with Marius Pharmaceuticals to bring KYZATREX®, an FDA-approved oral testosterone therapy, to Australia, broadening its men's health portfolio alongside SPONTAN®.
Read the ASX release: bit.ly/45YBIOo
$LTP #MensHealth
93% of treatment-experienced men seeking greater convenience and spontaneity reported improved erectile hardness and/or achieving penetration with SPONTAN®, in our largest real-world dataset for SPONTAN to date. Data to be presented at APCC this month. investors.ltrpharma.com/anno…
@LtrPharma SPONTAN® Phase II interim data: 10-minute median Tmax vs 60 minutes for oral vardenafil. LTR Pharma has also executed both core U.S. commercial agreements for the planned ROXUS® launch. Read the announcement: investors.ltrpharma.com/anno… $LTP
LTR Pharma has executed a definitive Compounding and Supply Agreement with Strive Pharmacy, establishing the manufacturing, compounding, fulfilment and national distribution framework for ROXUS® in the U.S. Read the release: investors.ltrpharma.com/anno… $LTP #menshealth #telehealth
$LTP has executed a definitive commercial agreement with Shed, converting the binding Term Sheet into a long-form agreement for U.S. launch of ROXUS® via Mavrox, with Shed committing to support delivery of not less than 150,000-units in first 12 months: investors.ltrpharma.com/anno…
LTR Pharma is expanding its intranasal platform beyond ED, with OROFLOW® entering formal clinical evaluation for OMD. The indication represents a projected US$8.1B global treatment market by 2034.
Read the ASX release: investors.ltrpharma.com/anno…
#LTP #LTRPharma #OROFLOW #pharma
Earlier this week, Shed gave ROXUS® its telehealth front door in the US. Today, Strive gives it the pharmacy that fills and ships the script. The route to market is now complete, ahead of first sales targeted for H1 CY2026. Read the ASX release: bit.ly/LTPStriveSpecialities $LTP
LTR Pharma’s U.S. telehealth partnership for ROXUS® has been covered by BiotechDispatch, highlighting its planned U.S. launch pathway with Shed Holdings.
Read more: bit.ly/4vJaZjQ
#LTP #LTRPharma #ASX #Biotech #ROXUS #MensHealth
LTR Pharma’s ROXUS® U.S. launch strategy continues to gain market attention, with StockWire X covering its telehealth-led commercial pathway with Shed Holdings. It’s worth a read: bit.ly/3SfrCVz
#LTP #LTRPharma #ASX #Biotech #ROXUS #MensHealth
LTR Pharma has been featured on Stockhead TV’s Break it Down, following the Company’s first U.S. commercial agreement for ROXUS®. Watch the segment here: bit.ly/4em0jR8
#LTRPharma #ASX #Biotech #MensHealth #ROXUS #USmarketentry #erectiledysfunction
LTR Pharma has established its first U.S. commercial route-to-market framework for ROXUS® through a binding term sheet with Shed, including a 150,000-unit first-year minimum commercial volume target, subject to key conditions.
Read the ASX release: bit.ly/4fz7Y0u
$LTP
SPONTAN® Phase II interim data: median Tmax of 10 minutes vs 60 minutes for oral vardenafil, consistent across adult and ≥65 populations, addressing a key FDA Pre-IND requirement.
Full ASX announcement: bit.ly/4eTDwxB
